[{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"PKX-001","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altamira Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Atlas Sciences"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IMT-002","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMolecular Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Balticgruppen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Balticgruppen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Balticgruppen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Balticgruppen Bio \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Series C Financing","leadProduct":"CT-868","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ Amgen"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ZT-01","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyldopa","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Ultra-concentrated Rapid Acting Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"LYFE Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"XW003","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ LYFE Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ LYFE Capital"},{"orgOrder":0,"company":"Celon Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CPL\u2019280","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Celon Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celon Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celon Labs \/ Not Applicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"ZT-01","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CPL\u2019280","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celon Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IDG16177","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Ildong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ildong Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"ZT-01","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methyldopa","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Melior Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adhera Therapeutics \/ Melior Pharmaceuticals I","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Melior Pharmaceuticals I"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inserm","sponsor":"T.H.A.C.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"ALF-5755","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Inserm \/ T.H.A.C.","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ T.H.A.C."},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Adocia"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Fast Acting Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Glucagon-like Peptide-1 Analogue","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ultra-Concentrated Rapid Acting Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ultra-Concentrated Rapid Acting Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ultra-Concentrated Rapid Acting Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"JATT Acquisition Corp","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"ZB-168","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"JATT Acquisition Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"JATT Acquisition Corp \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"JATT Acquisition Corp \/ Zura Bio"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"ZT-01","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science Corp","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science Corp","highestDevelopmentStatusID":"6","companyTruncated":"Wellbeing Digital Sciences \/ Nova Mentis Life Science Corp"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ultra Rapid Acting Prandial Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"OrsoBio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"TLC-3595","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/ OrsoBio"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Dong-A ST Co., Ltd. \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Wellington Management","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Wellington Management"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Demerger","leadProduct":"CT-388","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kimia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kimia Therapeutics \/ Carmot Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kimia Therapeutics \/ Carmot Therapeutics"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Indiana University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Eflornithine Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ Indiana University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Therapeutics \/ Indiana University School of Medicine"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Not Applicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zura Bio","sponsor":"JATT Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"ZB-168","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Zura Bio \/ JATT Acquisition","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ JATT Acquisition"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Crinetics Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"CRN04894","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Crinetics Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Crinetics Pharmaceuticals"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"DD01","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"D&D Pharmatech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"D&D Pharmatech \/ Not Applicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"C21","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Extend Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Extend Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Extend Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Extend Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Series E Financing","leadProduct":"CT-388","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Carmot Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"PeptiDream","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AZP-3813","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amolyt Pharma \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"Amolyt Pharma \/ PeptiDream"},{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ENT-03","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterin \/ Not Applicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"New Alliance Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"ECC5004","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Eccogene","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ New Alliance Capital","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/ New Alliance Capital"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.13,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT-996","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carmot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Imagine Pharma","sponsor":"IP Investors LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"IMG-1","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Imagine Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imagine Pharma \/ IP Investors LLC","highestDevelopmentStatusID":"6","companyTruncated":"Imagine Pharma \/ IP Investors LLC"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adhera Therapeutics \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Sessa Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Sessa Capital","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Sessa Capital"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"YCT-529","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"YourChoice Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"YCT529","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"PF-06954522","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Atrogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ATR-258","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Atrogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Atrogi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atrogi \/ Not Applicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tolimidone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"GB08","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Kexing Biopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kexing Biopharm \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CT-388","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CT-388","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"YCT529","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"YourChoice Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Not Applicable"}]

Find Endocrinology Drugs in Phase I Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : YCT529

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.

                          Brand Name : YCT-529

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 20, 2023

                          Lead Product(s) : YCT529

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Quotient

                          02

                          Lead Product(s) : CRN04894

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase I

                          Sponsor : Crinetics Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and t...

                          Brand Name : CRN04894

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 30, 2023

                          Lead Product(s) : CRN04894

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Crinetics Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Quotient

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : GZR18 tablet is an investigational, once-daily oral GLP-1 receptor agonist, which is being developing for the treatment of Type 2 Diabetes.

                          Brand Name : GZR18

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 12, 2024

                          Lead Product(s) : GZR18

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical development of company's lead product, SEP-786, which is being evaluated for the treatment of Hypoparathyroidism.

                          Brand Name : SEP-786

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 30, 2024

                          Lead Product(s) : SEP-786

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : J.P. Morgan

                          Deal Size : $331.2 million

                          Deal Type : Public Offering

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical development of company's lead product, SEP-786, which is being evaluated for the treatment of Hypoparathyroidism.

                          Brand Name : SEP-786

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 24, 2024

                          Lead Product(s) : SEP-786

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : J.P. Morgan

                          Deal Size : $288.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.

                          Brand Name : DehydraTECH-tirzepatide

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          October 09, 2024

                          Lead Product(s) : Tirzepatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The net proceeds will be used to fund the clinical development of company's lead product, SEP-786, which is being evaluated for the treatment of Hypoparathyroidism.

                          Brand Name : SEP-786

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 03, 2024

                          Lead Product(s) : SEP-786

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : J.P. Morgan

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          08

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : SEP-786 is a novel, potent, and selective, oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist. It is being developed for the treatment of patients with hypoparathyroidism.

                          Brand Name : SEP-786

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 27, 2024

                          Lead Product(s) : SEP-786

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.

                          Brand Name : NPM-115

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 04, 2024

                          Lead Product(s) : Exenatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase which increases phosphorylation of insulin substrate 1, being developed for the treatment of type 1 diabetes.

                          Brand Name : MLR-1023

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 16, 2024

                          Lead Product(s) : Tolimidone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank